Stack Labby Revive One
Browse/Peptide
Peptide

Semaglutide

01 / OVERVIEW

What this compound does

WHAT IT DOES

Semaglutide (Ozempic/Wegovy) is a proven, FDA-approved injection that lowers blood sugar and causes significant weight loss by curbing appetite.

KEY BENEFITS
~15% average weight loss (Wegovy)
Strong blood-sugar control
Proven cardiovascular risk reduction
BEST FOR
  • • People with type 2 diabetes
  • • Adults with obesity/overweight meeting criteria
WHAT TO EXPECT

Weekly injection (or daily oral Rybelsus); appetite drops and weight falls over months. Requires a prescription.

WHO SHOULD AVOID THIS
  • • Personal/family history of medullary thyroid carcinoma or MEN2
  • • Pregnant people
  • • History of pancreatitis (caution)
MYTHS & FACTS
Myth:
Fact:
Myth:
Fact:
At a glance
Typical dose
1.0-2.4 mg subcutaneously once weekly (approved)
Loading: Titrate 0.25 mg/week upward monthly
Evidence
—
Studies indexed3
How it's made

Manufactured to pharmacopeial standards as a stable acylated GLP-1 analog.

03 / DOSAGE

How much, when

MAINTENANCE

1.0-2.4 mg subcutaneously once weekly (approved)

LOADING PROTOCOL

Titrate 0.25 mg/week upward monthly

weekly injection, titrated

TIMING

Semaglutide — Any dose

Standard dosing.

02 / EVIDENCE

Peer-reviewed studies

  • PMID: 33567185

    Significant weight loss

    STEP trials showed ~15% mean body-weight reduction with weekly semaglutide 2.4 mg vs placebo.

    A
  • PMID: 27633186

    Glycemic control

    SUSTAIN trials demonstrated robust HbA1c reduction in type 2 diabetes.

    A
  • PMID: 37952131

    Cardiovascular benefit

    SELECT trial showed reduced major cardiovascular events in overweight/obese patients without diabetes.

    A
  • PMID 33567185 · 2021rct

    Once-weekly semaglutide in adults with overweight or obesity (STEP 1)

    ~15% weight loss

    A
  • PMID 37952131 · 2023rct

    Semaglutide and cardiovascular outcomes (SELECT)

    Reduced MACE

    A
04 / INTERACTIONS

Medicine interactions

  • Insulin / sulfonylureas· antidiabetic

    Additive glucose lowering raises hypoglycemia risk.

    → Dose reductions often needed; monitor glucose.

    HIGH

  • Oral medications (delayed gastric emptying)· various

    Slowed gastric emptying can alter absorption timing.

    → Monitor drugs with narrow therapeutic windows.

    LOW

This page is a reference summary, not a prescription. Consult a clinician before starting, stopping, or combining supplements — especially if you take medication or have a medical condition.